5 Best High Growth Healthcare Stocks to Buy

4. Genmab A/S (NASDAQ:GMAB)

Number of Hedge Fund Holders: 14

Founded in Copenhagen, Denmark in 1999, Genmab A/S (NASDAQ:GMAB) is an international biotechnology company on developing innovative and differentiated antibody therapeutics. Its pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

On November 7, Genmab A/S (NASDAQ:GMAB) released its financial results for 9M 2023. Its revenue increased by 26% y-o-y to DKK 11.8 billion while net income decreased by 25% y-o-y to DKK 3.7 billion.

As of Q3 2023, Genmab A/S (NASDAQ:GMAB) shares were held by 14 hedge funds. Jim Simons’ Renaissance Technologies was the largest hedge fund shareholder with ownership of 1.2 million shares valued at $41 million.